定量乙肝表面抗原水平在未接受治疗的慢性乙肝患者预测肝

StephenW

Clin Exp Hepatol. 2020 Feb;6(1):55-59. doi: 10.5114/ceh.2020.93058. Epub 2020 Feb 17.
Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients.
Tatar B1, Acar A1, Adar P1, Kose S1.
Author information

1
    Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Izmir Tepecik Education and Research Hospital, Turkey.

Abstract
Aim of the study:

The quantitative hepatitis B surface antigen (qHBsAg) level indicates the amount of transcriptional activity of covalently closed circular DNA (cccDNA) and integrated DNA in hepatocytes which plays a role in development of chronic hepatitis B (CHB) and may help decide whether the treatment is necessary or not. The aim of this study is to evaluate the association between serum qHBsAg levels and viral replication and stage of liver fibrosis in treatment-naive CHB patients and to determine the role of qHBsAg levels in predicting when liver biopsy is necessary.
Material and methods:

967 patients were included in the study. Because of refusal of liver biopsy the study was conducted on 123 patients. The association between qHBsAg levels with HBV DNA, a-fetoprotein, fibrosis stage and histology activity index was evaluated.
Results:

Of the patients, mean age was 48 ±11.2 years and 56.1% were male. We found that patients with HBV DNA ≥ 2000 IU/ml had a higher qHBsAg titer in comparison with HBV DNA < 2000 IU/ml. However, there was no relationship between qHBsAg titer and liver necroinflammation or fibrosis stage.
Conclusions:

Monitoring of qHBsAg together with HBV DNA may be helpful in CHB management. However, qHBsAg level does not provide knowledge about the timing of biopsy or the decision of CHB treatment.

Copyright: © 2020 Clinical and Experimental Hepatology.
KEYWORDS:

chronic hepatitis B; hepatocytes; liver biopsy; quantitative hepatitis B surface antigen

PMID:
    32166125
PMCID:
    PMC7062122
DOI:
    10.5114/ceh.2020.93058

Free PMC Article

StephenW

Clin Exp Hepatol。 2020年2月； 6（1）：55-59。 Doi：10.5114 / ceh.2020.93058。 Epub 2020 2月17。
定量乙肝表面抗原水平在未接受治疗的慢性乙肝患者预测肝活检时间中的作用。
塔塔尔（Tatar）B1，阿卡（Acar）A1，阿达（Adar）P1，高丝（Kose）S1
作者信息

1个
卫生科学大学传染病和临床微生物学系，土耳其伊兹密尔特佩西克教育与研究医院。

抽象
研究目的：

定量的乙型肝炎表面抗原（qHBsAg）水平表明肝细胞中共价闭合环状DNA（cccDNA）和整合的DNA的转录活性的量在慢性乙型肝炎（CHB）的发展中发挥作用，并可能有助于决定是否治疗是否必要。这项研究的目的是评估未接受治疗的CHB患者的血清qHBsAg水平与病毒复制和肝纤维化阶段之间的关联，并确定qHBsAg水平在预测何时需要进行肝活检中的作用。
材料与方法：

967名患者被纳入研究。由于拒绝进行肝活检，因此对123例患者进行了研究。评估了qHBsAg水平与HBV DNA，甲胎蛋白，纤维化分期和组织学活性指数之间的关系。
结果：

在这些患者中，平均年龄为48±11.2岁，男性为56.1％。我们发现，与HBV DNA <2000 IU / ml相比，HBV DNA≥2000 IU / ml的患者的qHBsAg滴度更高。但是，qHBsAg滴度与肝坏死性炎症或纤维化分期无关。
结论：

监测qHBsAg和HBV DNA可能有助于CHB管理。但是，qHBsAg水平不能提供有关活检时间或CHB治疗决策的知识。

版权所有：©2020临床和实验肝病学。
关键字：

慢性乙型肝炎肝细胞肝活检定量乙肝表面抗原

PMID：
32166125
PMCID：
PMC7062122
DOI：
10.5114 / ceh.2020.93058

免费PMC文章

StephenW

https://www.termedia.pl/Journal/ ... of quantitative.pdf